Summit Therapeutics

Yahoo Finance • 3 months ago

Summit Therapeutics Inc. (SMMT): Hedge Funds Are Bullish On This NASDAQ Stock Right Now

We recently compiled a list of the 10 Best Performing NASDAQ Stocks in 2024.In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other great performing NASDAQ stocks. Market Expec... Full story

Yahoo Finance • 3 months ago

Is Summit Therapeutics Inc. (SMMT) the Best Performing Stock in 2024?

We recently compiled a list of the 10 Best Performing Stocks in 2024.In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against the other great-performing stocks. Dow Breaks Record The Dow... Full story

Yahoo Finance • 3 months ago

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of artificial intelligence, and its revenue, earnings, and stock price continue to grow incredibly fast. Nvidia's shares... Full story

Yahoo Finance • 3 months ago

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally... Full story

Yahoo Finance • 3 months ago

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half Sunday, Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMON... Full story

Yahoo Finance • 5 months ago

Summit Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Development of Ivonescimab

Five Year Collaboration Intended to Advance PD-1 / VEGF Bispecific in Several Solid Tumors across Multiple Clinical Trials MIAMI & HOUSTON, July 25, 2024--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "C... Full story

Yahoo Finance • 6 months ago

3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street

Never ignore the power of momentum. Sometimes the fastest-moving objects are the ones that keep on racing ahead. That could be the case with a select group of stocks that have delivered tremendous gains this year. These three stocks have... Full story

Yahoo Finance • 7 months ago

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio... Full story

Yahoo Finance • 9 months ago

Insiders Are Buying These 11 Penny Stocks

In this article, we will take a detailed look at Insiders Are Buying These 11 Penny Stocks. For a quick overview of such stocks, read our article Insiders Are Buying These 5 Penny Stocks. US stock market started the second quarter of 2024... Full story

Yahoo Finance • 10 months ago

Q4 2023 Summit Therapeutics Inc Earnings Call

Participants David Ganzarcz; Chief Business & Strategy Officer; Summit Therapeutics Inc Bob Duggan; CEO & Chairman; Summit Therapeutics Inc Maky Zanganeh; CEO & President‍; Summit Therapeutics Inc Ankur Dhingra; Chief Financial Officer... Full story

Yahoo Finance • 10 months ago

Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024

Conference Call to be Held at 9:00am ET MIAMI, Fla., February 14, 2024--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 20... Full story

Yahoo Finance • 2 years ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

First US Patient Treated in Ivonescimab Clinical Trial after Closing Agreement; $500M Raised in Fully-Subscribed Rights Offering MENLO PARK, Calif., May 11, 2023--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," o... Full story

Yahoo Finance • 2 years ago

Why Shares of Summit Therapeutics Soared This Week

Summit Therapeutics advanced its lead therapy into two phase 3 trials to treat non-small cell lung cancer. Continue reading... Full story

Yahoo Finance • 2 years ago

8 Best Insider Trading Websites in 2023

In this article, we will take a look at the 8 best insider trading websites in 2023. If you want to explore similar websites, you can also take a look at 3 Best Insider Trading Websites in 2023. An insider is a person who has access to no... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Summit Therapeutics Inc. (SMMT) and Encourages SMMT Investors to Contact the Firm

PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit”) on behalf of the Company’s shareholders. The investigation seeks to determine whether... Full story

Yahoo Finance • 2 years ago

SUMMIT INVESTOR ALERT: Kaskela Law LLC Announces Stockholder Investigation of Summit Therapeutics Inc. (SMMT) and Encourages SMMT Investors to Contact the Firm

PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit”) on behalf of the Company’s investors. The investigation seeks to determine whether Sum... Full story

Yahoo Finance • 2 years ago

Why Summit Therapeutics Stock Is Skyrocketing This Week

Shares of Summit Therapeutics (NASDAQ: SMMT) were skyrocketing 371.8% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. This huge gain came after the company announced on Tue... Full story

Yahoo Finance • 2 years ago

Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization in the United States, Canada, Europe, and Japan. Akeso Inc. will retain development and commercializatio... Full story

Yahoo Finance • 2 years ago

Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody

Menlo Park, California, US, and Grand Cayman, Cayman Islands, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced a definitive agreement of its partnership with Ake... Full story

Yahoo Finance • 2 years ago

Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effec... Full story